- New White House rules would require political appointees to approve all federal research grants before they’re awarded.
- Scientific peer review — the longstanding standard for research grants at NIH and NSF — would be reduced to an advisory role only.
- The 412-page proposal gives the OMB, headed by Project 2025 architect Russell Vought, sweeping new authority over science spending.
- The public has just 45 days to comment on the changes — an unusually short window for a proposal of this scale.
- New White House rules would require political appointees to approve all federal research grants before they’re awarded.
- Scientific peer review — the longstanding standard for research grants at NIH and NSF — would be reduced to an advisory role only.
- The 412-page proposal gives the OMB, headed by Project 2025 architect Russell Vought, sweeping new authority over science spending.
- The public has just 45 days to comment on the changes — an unusually short window for a proposal of this scale.
The Proposal That Could Reshape Research Grants Forever
The White House has released a 412-page draft regulation that would hand political appointees the final say over federal research grants — effectively inserting partisan gatekeeping into a process that has, for decades, been governed by scientific expertise. Published for official notice in the Federal Register, the proposal centralises control under the Office of Management and Budget, currently directed by Russell Vought, the chief architect of the Heritage Foundation’s Project 2025 blueprint for the Trump administration.
This isn’t a procedural tweak. If enacted, it would fundamentally change how the U.S. decides which science gets funded — and, by extension, which science gets done. The stakes are hard to overstate. The NIH alone funds tens of thousands of research grants every year, spanning cancer biology, infectious disease, neuroscience, and much more. The NSF underpins enormous swathes of basic research across universities nationwide. What happens to those funding pipelines doesn’t just affect labs — it shapes what medicines get developed, what technologies emerge, and how competitive American science remains globally.
How Research Grants Have Always Worked — Until Now
For those unfamiliar with how federal research grants actually get approved, here’s the short version: scientists submit proposals, and panels of other scientists — experts in the relevant field — evaluate them on their merits. This peer review process has been the backbone of U.S. science funding since the mid-20th century. It’s imperfect, sure, but it’s designed around one core principle: the best science should win, not the most politically convenient science.
The new OMB proposal would break that model. Under the draft rules, peer review panels at agencies like NIH and NSF would still exist — but their verdicts would become purely advisory. The proposal states explicitly that peer review “remains advisory and does not replace agency discretion.” Final approval would rest with senior political appointees, who would be required to evaluate research grants for compliance with presidential priorities, including those related to race and gender.
To be clear about what that means in practice: a career immunologist’s grant proposal could be approved or killed not because of its scientific quality, but because a political appointee decided it didn’t align with the administration’s current ideological agenda. That’s a profound departure from how science funding has worked in America.
The Political Backdrop
The proposal doesn’t emerge from a vacuum. The OMB’s draft explicitly references what it calls a “‘woke’ policy agenda that deliberately favored certain identity groups over others” under the Biden administration as justification for reform. That framing tells you a lot about the ideological lens through which this overhaul was designed.
Earlier in Trump’s second term, the administration tried a more blunt approach — abruptly terminating thousands of existing research grants. Courts found those terminations illegal. This new regulatory framework appears to be, at least in part, a legal workaround: rather than yanking grants after the fact (which courts won’t allow), the rules would give the administration control over which grants get approved in the first place, and would explicitly permit “termination based on the discretion of the Federal agency.” It’s a structural end-run around judicial oversight.
The administration also previously attempted to cap indirect cost reimbursement rates at 15 percent — a move Congress rejected. The new proposal doesn’t revive that specific fight, but it does take a softer stab at the same target: it calls for preferring grant recipients with lower overhead rates and restricts funding for publication costs unless specifically pre-approved by the agency.
What Scientists and Advocates Are Saying
The reaction from the scientific community has been sharp and largely unified. “We warned of this exact form of government overreach in science a year ago,” said Colette Delawalla, founder of science advocacy group Stand Up for Science. “It replaces expertise with political appointees, globally decouples the U.S. and completely guts our scientific ecosystem.”
Jules Barbati-Dajches of the Center for Science and Democracy at the Union of Concerned Scientists was equally direct: “The OMB’s proposed rule is an escalation of the administration’s relentless attacks on independent science. It replaces scientific merit with a political loyalty test and could be used to silence research that is politically inconvenient to the administration.” Barbati-Dajches went further, warning the proposal would effectively give “politically connected industries a functional veto over research that might reveal risks associated with products and practices.” That last point deserves attention — it’s not difficult to imagine how that dynamic could play out in areas like pharmaceutical safety, pesticide regulation, or fossil fuel emissions research.
Elizabeth Ginexi, a former NIH program official, offered perhaps the most precise characterisation in her analysis of the rules: “What OMB is proposing is not a reform of grants management. It is a complete political control apparatus layered over every stage of the federal science funding lifecycle.”
The Fine Print: International Collaboration and Conference Restrictions
Beyond the headline-grabbing shift in approval authority, the proposal contains several other provisions that would reshape how research grants actually function day to day.
International research collaboration — a standard feature of modern science, where teams routinely span multiple countries and institutions — would be permitted only on a case-by-case basis and actively disfavoured relative to domestic-only work. In fields like particle physics, climate science, and genomics, where global collaboration isn’t optional so much as fundamental to the work, this could be crippling.
Conference attendance — where scientists present findings, gather feedback, and build the informal networks that drive discovery — would require prior written approval in the grant itself. Given that many conferences are announced after a grant is written and approved, this creates a bureaucratic catch-22 that effectively discourages participation in the scientific community’s core knowledge-sharing infrastructure.
Publication costs, too, would face restrictions. Open-access publishing fees — increasingly required by journals and mandated by prior federal policy — would be disallowed unless pre-approved agency by agency. That cuts directly against the broader push toward open science that has gained momentum across the research world over the past decade.
A 45-Day Window — and What Happens Next
The public comment period for the proposed rules runs just 45 days. Matt Owens, president of the Council on Government Relations — which represents more than 150 research universities — flagged that as unusually short given the scope of what’s being proposed. Standard regulatory practice for major rule changes typically allows 60 to 90 days, sometimes longer. The compressed timeline limits the ability of universities, scientific societies, patient advocacy groups, and individual researchers to mount organised, detailed responses.
Whether the rules survive legal challenge is another question. Courts have already pushed back on this administration’s attempts to unilaterally terminate research grants without proper process. Regulatory experts will be watching closely to see whether this proposal clears the procedural hurdles required under the Administrative Procedure Act — and advocacy groups are almost certainly already preparing litigation strategies in parallel with their public comments.
What’s clear is that the U.S. scientific enterprise is being asked to operate under conditions of deepening political uncertainty. Researchers who depend on federal research grants for their labs, their staff, and their careers are now facing a funding environment where scientific merit may matter less than ideological alignment. Historically, when that happens — whether in the Soviet Union’s suppression of genetics under Lysenkoism or in any number of other cautionary tales — the long-term damage to a nation’s scientific capacity is severe and slow to reverse. That’s the trajectory worth watching here.
